Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Spirocarbocyclic iminothiadiazine dioxide scaffolds: MerckRecent Research Landscape

Misfolded protein aggregation in neurodegenerative pathology leads to irreversible neuronal loss. These engineered peptide sequences selectively bind and neutralize toxic proteoforms to halt disease progression.

What technical problems is Merck addressing in Spirocarbocyclic iminothiadiazine dioxide scaffolds?

Pathological alpha-synuclein protein aggregation

(3)evidences

Abnormal accumulation of alpha-synuclein leads to neurodegenerative cellular dysfunction. Preventing this degradation mechanism stops the progression of synucleinopathies.

Neurotoxic protein aggregate accumulation

(1)evidences

Excessive buildup of neurotoxic protein aggregates leads to progressive cognitive decline. Reducing these deposits prevents neuronal death and halts disease progression.